Press release from BoneSupport
The medical technology company BONESUPPORT AB in Lund, which develops synthetic, injectable ceramic bone substitute, has received SEK 135 million from a new share issue.
The new investors include the venture capital companies HealthCap of Stockholm and NBGI Venture of London. The new funds will mainly be used for the impending launch of BONESUPPORT’s first product CERAMENT|BONE VOID FILLER, to expand patient studies of the main product CERAMENT|SPINE SUPPORT, and to continue developing the company’s R&D pipeline.
The new share issue means BONESUPPORT will expand ownership in the company
with venture capital companies HealthCap and NBGI joining existing owners, including, Innovationskapital, Teknoinvest and FERD Venture, to give a capital injection of SEK 135 million.
“Skeletal disease is a widespread and growing modern-day problem. Our research and the studies we have carried out also show a very large potential for our products. The new funds mean that we will now be able to invest more heavily in launching our first product, CERAMENT|BONE VOID FILLER,” says BONESUPPORT’s CEO FredrikLindberg.
BONESUPPORT focuses on developing products based on injectable ceramic bone
substitute mainly for the treatment of bone defects and osteoporosis. The market for
bone graft material is estimated at around USD 2 billion with an annual increase of over 25 per cent. BONESUPPORT’s synthetic bone substitute CERAMENT|BONE VOID
FILLER has been approved by the FDA for launch on the US market. The product is
aimed at the spinal fusion segment as well as broader orthopaedic applications. The US launch is scheduled for the end of 2006. After this the product will be launched in Europe and Asia.
“BONESUPPORT is ready to breakthrough onto the market in an area with vast potential. It’s marvellous for NBGI to find a Swedish company in this exciting segment that meets the high demands we set. This says a great deal about the belief and expectations we have in BONESUPPORT,” says Aris Constantinides partner at NBGI Ventures.
In connection with the new share issue Dr. Björn Odlander, partner/founder of HealthCap and Aris Konstantinides, a partner at NBGI Venture will become members ofBONESUPPORT’s board of directors.
For further information, please contact:
Fredrik Lindberg, CEO BoneSupport
Tel. +46 (0)46 286 53 79 or +46 (0)708 86 53 70
The medical technology company BONESUPPORT AB in Lund, which develops synthetic, injectable ceramic bone substitute, has received SEK 135 million from a new share issue.
The new investors include the venture capital companies HealthCap of Stockholm and NBGI Venture of London. The new funds will mainly be used for the impending launch of BONESUPPORT’s first product CERAMENT|BONE VOID FILLER, to expand patient studies of the main product CERAMENT|SPINE SUPPORT, and to continue developing the company’s R&D pipeline.
The new share issue means BONESUPPORT will expand ownership in the company
with venture capital companies HealthCap and NBGI joining existing owners, including, Innovationskapital, Teknoinvest and FERD Venture, to give a capital injection of SEK 135 million.
“Skeletal disease is a widespread and growing modern-day problem. Our research and the studies we have carried out also show a very large potential for our products. The new funds mean that we will now be able to invest more heavily in launching our first product, CERAMENT|BONE VOID FILLER,” says BONESUPPORT’s CEO FredrikLindberg.
BONESUPPORT focuses on developing products based on injectable ceramic bone
substitute mainly for the treatment of bone defects and osteoporosis. The market for
bone graft material is estimated at around USD 2 billion with an annual increase of over 25 per cent. BONESUPPORT’s synthetic bone substitute CERAMENT|BONE VOID
FILLER has been approved by the FDA for launch on the US market. The product is
aimed at the spinal fusion segment as well as broader orthopaedic applications. The US launch is scheduled for the end of 2006. After this the product will be launched in Europe and Asia.
“BONESUPPORT is ready to breakthrough onto the market in an area with vast potential. It’s marvellous for NBGI to find a Swedish company in this exciting segment that meets the high demands we set. This says a great deal about the belief and expectations we have in BONESUPPORT,” says Aris Constantinides partner at NBGI Ventures.
In connection with the new share issue Dr. Björn Odlander, partner/founder of HealthCap and Aris Konstantinides, a partner at NBGI Venture will become members ofBONESUPPORT’s board of directors.
For further information, please contact:
Fredrik Lindberg, CEO BoneSupport
Tel. +46 (0)46 286 53 79 or +46 (0)708 86 53 70
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
